Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Author Information
Author(s): Anju Singh, Vikas Misra, Rajesh K Thimmulappa, Hannah Lee, Stephen Ames, Mohammad O Hoque, James G Herman, Stephen B Baylin, David Sidransky, Edward Gabrielson, Malcolm V Brock, Shyam Biswal
Primary Institution: Johns Hopkins University
Hypothesis
Changes in KEAP1 might underlie the drug resistance seen in lung cancer.
Conclusion
Biallelic inactivation of KEAP1 is a frequent genetic alteration in NSCLC, leading to increased NRF2 activity and resistance to chemotherapy.
Supporting Evidence
- Biallelic inactivation of KEAP1 was found in 19% of NSCLC samples.
- Loss of KEAP1 function leads to increased NRF2 activity.
- NRF2 activation is associated with resistance to chemotherapy.
- Mutations in KEAP1 were identified in both cell lines and tumor samples.
- High NRF2 activity was linked to increased expression of detoxification enzymes.
- Patients with KEAP1 mutations showed poorer responses to chemotherapy.
Takeaway
This study found that a common mutation in lung cancer makes it harder for patients to respond to chemotherapy because it helps cancer cells survive.
Methodology
The study involved sequencing KEAP1 in 12 cell lines and 54 NSCLC samples, along with loss of heterozygosity analysis.
Potential Biases
Potential bias in sample selection and analysis methods.
Limitations
The study's sample size may not be large enough to draw definitive conclusions.
Participant Demographics
The study included lung cancer patients with various tumor types, primarily adenocarcinomas.
Statistical Information
P-Value
0.0016
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website